PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.71%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
1.74%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-18.30%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.30%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
3.42%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.42%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
3.42%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-3.31%
Dividend reduction while AVGO stands at 0.14%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
92.86%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
237.50%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-16.43%
Negative 10Y revenue/share CAGR while AVGO stands at 409.54%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-2.34%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-18.48%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
23.60%
10Y OCF/share CAGR under 50% of AVGO's 441.92%. Michael Burry would worry about a persistent underperformance in cash creation.
10.68%
Below 50% of AVGO's 73.80%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-41.48%
Negative 3Y OCF/share CAGR while AVGO stands at 34.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-18.75%
Negative 10Y net income/share CAGR while AVGO is at 691.11%. Joel Greenblatt sees a major red flag in long-term profit erosion.
110.54%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-90.75%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
285.08%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
66.14%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-14.43%
Negative 3Y equity/share growth while AVGO is at 188.08%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
15.94%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
1.45%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
7.83%
Below 50% of AVGO's 38.29%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
5.49%
AR growth is negative/stable vs. AVGO's 14.59%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
13.38%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.66%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-1.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-12.30%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
3.92%
R&D dropping or stable vs. AVGO's 19.53%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
8.97%
SG&A growth well above AVGO's 14.12%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.